Journal of Cancer Research and Clinical Oncology 2022

5 papers
The 2022 edition of the Journal of Cancer Research and Clinical Oncology focused on integrating multi-parametric and multimodal data to enhance disease diagnostics and personalized risk stratification. Research themes centered on bridging retrospective discoveries with prospective clinical validation, particularly in predicting postoperative outcomes from preoperative data and standardizing thresholds for emerging biomarkers. Notable contributors to this year’s discourse included Bhumsuk Keam, Dae Seog Heo, and Dong-Wan Kim. Specific studies investigated therapeutic mechanisms and prognostic indicators across various malignancies. Research explored the correlation between monalizumab efficacy and HLA-E expression in head and neck squamous carcinoma, as well as the role of sorafenib in modulating the immunosuppressive microenvironment in osteosarcoma. Clinical evaluations addressed the use of nimotuzumab in nasopharyngeal carcinoma and the prognostic significance of hepatocyte growth factor in muscle-invasive bladder cancer. Additionally, the edition featured detailed case reviews on rare conditions, such as early T-cell precursor lymphoblastic leukemia mimicking other neoplasms. These works highlight a trend toward refining clinical thresholds and utilizing integrated data for more robust diagnostic and therapeutic strategies.

Top Research Directions

The 5 research directions with Journal of Cancer Research and Clinical Oncology 2022 papers, ranked by paper count. Share is the fraction of the edition’s papers in the direction.

#DirectionPapersShare
1Closing the Intermediate Risk Stratification Gap120.0%
2Prospective Validation of Clinical Biomarkers120.0%
3Quantifying Biological Heterogeneity Beyond Anatomical Staging120.0%
4Selection Bias in Historical Clinical Datasets120.0%
5Standardizing Diagnostic Thresholds for Clinical Biomarkers120.0%

Download all directions as CSV

Institutions

Institutions credited by Journal of Cancer Research and Clinical Oncology 2022 papers: a paper credits every institution named in its affiliations, once. 16 institutions share 3 credited papers.

#InstitutionPapersShare20212021 rank
1019tepx80 133.3%0—
202f3xk561 133.3%0—
3Brigham and Women's Hospital 133.3%0—
4Centre Hospitalier de l'Université de Montréal 133.3%0—
5Chinese University of Hong Kong 133.3%0—
6Medical University of Vienna 133.3%0—
7Okayama University 133.3%0—
8Ruijin Hospital 133.3%0—
9Seoul National University 133.3%0—
10Seoul National University Hospital 133.3%0—
11Shanghai Jiao Tong University 133.3%0—
12The University of Texas Southwestern Medical Center 133.3%0—
13University of Jordan 133.3%0—
14Université de Montréal 133.3%0—
15Vita-Salute San Raffaele University 133.3%0—
16Weill Cornell Medicine 133.3%0—

Download all institutions as CSV

About this data

Papers. Journal of Cancer Research and Clinical Oncology 2022 lists 5 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.

Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers.

Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 3 of 5 papers (60.0%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.

Data. Counts come from Lacuna’s data build of 2026-11-20 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “Journal of Cancer Research and Clinical Oncology 2022”, https://lacuna.tiptreesystems.com/venue/journal-of-cancer-research-and-clinical-oncology/2022.

Top Authors

AuthorPapers
Jeongjae Lee1
Jeremy Yuen-Chun Teoh1
Qiyuan Bao1

Impactful Papers

Papers from Journal of Cancer Research and Clinical Oncology 2022 that shaped research clusters.

Influential

Papers

Title
Concurrent chemoradiotherapy combined with nimotuzumab in stage III–IVa nasopharyngeal carcinoma: a retrospective analysis
Early T-cell precursor lymphoblastic leukemia accompanied by prominent blastic plasmacytoid dendritic cell proliferation mimicking blastic plasmacytoid dendritic cell neoplasm: an exceptional case rep
Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines
Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer
Sorafenib inhibits doxorubicin-induced PD-L1 upregulation to improve immunosuppressive microenvironment in Osteosarcoma